Therapeutic activation of Vα24+Vβ11+ +NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity

Blood

Volumn 103, Issue 2, 2004, Pages 383-389

  Nieda, Mie ^b   Okai, Miki ^b   Tazbirkova, Andrea ^b   Lin, Henry ^b   Yamaura, Ayako ^b   Ide, Kazuki ^b   Abraham, Rick ^b   Juji, Takeo ^b   Macfarlane, David J ^b   Nicol, Andrew J ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD1D ANTIGEN; CD69 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 4; CD1 ANTIGEN; LEUKOCYTE ANTIGEN;

ADULT; AGED; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; BREAST CANCER; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; KIDNEY CARCINOMA; LIVER CANCER; LUNG ADENOCARCINOMA; MALE; MELANOMA; NATURAL KILLER CELL; NATURAL KILLER T CELL; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; BLOOD; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; METASTASIS; MIDDLE AGED; NEOPLASM; PATHOLOGY;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD1; B-LYMPHOCYTES; FEMALE; HUMANS; IMMUNITY, NATURAL; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-12; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; T-LYMPHOCYTES;

EID: 0942276861     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-04-1155     Document Type: Article

References (41)

1. Nieda M, Nicol A, Koezuka Y, et al. Activation of human Valpha24NKT cells by alpha-glycosylceramide in a CD1d-restricted and Valpha24TCR-mediated manner. Hum Immunol. 1999;60:10-19.
2. Exley M, Porcelli S, Furman M, Garcia J, Balk S. CD161 (NKR-P1A) costimulation of CD1d-dependent activation of human T cells expressing invariant V alpha 24 J alpha Q T cell receptor alpha chains. J Exp Med. 1998;188:867-876.
3. Spada FM, Koezuka Y, Porcelli SA. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J Exp Med. 1998;188:1529-1534.
4. Kawano T, Cui J, Koezuka Y, et al. CD1d-restricted and TCR-mediated activation of Valpha14 NKT cells by glycosylceramides. Science. 1997;278:1626-1629.
5. Brossay L, Chioda M, Burdin N, et al. CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med. 1998;188:1521-1528.
6. Nakagawa R, Motoki K, Ueno H, et al. Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-galactosylceramide, KRN7000. Cancer Res. 1998;58:1202-1207.
7. Toura I, Kawano T, Akutsu Y, Nakayama T, Ochiai T, Taniguchi M. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide. J Immunol. 1999;163:2387-2391.
8. Nieda M, Nicol A, Koezuka Y, et al. TRAIL expression by activated human CD4(+)V alpha 24+NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. Blood. 2001;97:2067-2074.
9. Kikuchi A, Nieda M, Schmidt C, et al. In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma. Br J Cancer. 2001;85:741-746.
10. Kitamura H, Ohta A, Sekimoto M, et al. alpha-galactosylceramide induces early B-cell activation through IL-4 production by NKT cells. Cell Immunol. 2000;199:37-42.
11. Nishimura T, Kitamura H, Iwakabe K, et al. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cell induces the differentiation of antigen-specific cytotoxic T lymphocytes. Int Immunol. 2000;12:987-994.
12. Smyth MJ, Crowe NY, Pellicci DG, et al. Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood. 2002;99:1259-1266.
13. Hayakawa Y, Takeda K, Yagita H, et al. Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide. Eur J Immunol. 2001;31:1720-1727.
14. Nakagawa R, Nagafune I, Tazunoki Y, et al. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice. J Immunol. 2001;166:6578-6584.
15. Metelitsa LS, Naidenko OV, Kant A, et al. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol. 2001;167:3114-3122.
16. Carnaud C, Lee D, Donnars O, et al. Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol. 1999;163:4647-4650.
17. Eberl G, MacDonald HR. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur J Immunol. 2000;30:985-992.
18. Giaccone G, Punt CJ, Ando Y, et al. A phase I study ȯf the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res. 2002;8:3702-3709.
19. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol. 2002;3:867-874.
20. Tomura M, Yu WG, Ahn HJ, et al. A novel function of Valpha14+CD4+NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system. J Immunol. 1999;163:93-101.
21. Kitamura H, Iwakabe K, Yahata T, et al. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med. 1999;189:1121-1128.
22. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994;179:1109-1118.
23. Okai M, Nieda M, Tazbirkova A, et al. Human peripheral blood Valpha24+ Vbeta11+ NKT cells expand following administration of alpha-galactosylceramide-pulsed dendritic cells. Vox Sang. 2002;83:250-253.
24. Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res. 1999;59:56-58.
25. Naumov YN, Bahjat KS, Gausling R, et al. Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets. Proc Natl Acad Sci U S A. 2001;98:13838-13843.
26. Lehuen A, Lantz O, Beaudoin L, et al. Overexpression of natural killer T cells protects Valpha14- Jalpha281 transgenic nonobese diabetic mice against diabetes. J Exp Med. 1998;188:1831-1839.
27. Sharif S, Arreaza GA, Zucker P, Delovitch TL. Regulatory natural killer T cells protect against spontaneous and recurrent type 1 diabetes. Ann N Y Acad Sci. 2002;958:77-88.
28. Gonzalez-Aseguinolaza G, de Oliveira C, Tomaska M, et al. alpha-galactosylceramide-activated Valpha 14 natural killer T cells mediate protection against murine malaria. Proc Natl Acad Sci U S A. 2000;97:8461-8466.
29. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med. 2000;192:921-930.
30. Zeng DF, Lewis D, Deibakhsh-Jones S, et al. Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease. J Exp Med. 1999;189:1073-1081.
31. Ishihara S, Nieda M, Kitayama J, et al. CD8(+)NKR-P1A(+)T cells preferentially accumulate in human liver. Eur J Immunol. 1999;29:2406-2413.
32. Osman Y, Kawamura T, Naito T, et al. Activation of hepatic NKT cells and subsequent liver injury following administration of alpha-galactosylceramide. Eur J Immunol. 2000;30:1919-1928.
33. Enomoto A, Nishimura H, Yoshikai Y. Predominant appearance of NK1.1+ T cells producing IL-4 may be involved in the increased susceptibility of mice with the beige mutation during Salmonella infection. J Immunol. 1997;158:2268-2277.
34. Ishigami M, Nishimura H, Naiki Y, et al. The roles of intrahepatic Valpha14(+) NK1.1(+) T cells for liver injury induced by Salmonella infection in mice. Hepatology. 1999;29:1799-1808.
35. Yang OO, Racke FK, Nguyen PT, et al. CD1d on myeloid dendritic cells stimulates cytokine secretion from and cytolytic activity of Vα24JαQ T cells: a feedback mechanism for immune regulation. J Immunol. 2000;165:3756-3762.
36. Matsuda JL, Naidenko OV, Gapin L, et al. Tracking the response of natural killer T cells to a glycolipid antigen using CD1 d tetramers. J Exp Med. 2000;192:741-754.
37. Wilson MT, Johanson C, Olivares-Villagomez D, et al. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Prod Natl Acad Sci U S A. 2003;100:10913-10918.
38. Crowe NY, Uldrich AP, Kyparissoudis K, et al. Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J Immunol. 2003;171:4020-4070.
39. Motohashi S, Kobayashi S, Ito T, et al. Preserved IFN-γ production of circulating Vα24 NK T cells in primary lung cancer patients. Int J Cancer. 2002;102:159-165.
40. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells [comment appears in Nat Med. 1998;4:269-270]. Nat Med. 1998;4:328-332.
41. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells [comment appears in Nat Med. 1998;4:269-270]. Nat Med. 1998;4:328-332.